Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) reported that it bought back 1.46 million H-shares on the Hong Kong Stock Exchange on 14 September 2026. The repurchased shares represent 0.27% of the company’s issued share capital (excluding treasury shares) as of 11 September 2026.

The shares were acquired at prices ranging between HKD 16.30 and HKD 17.14, with a volume-weighted average cost of HKD 16.98 per share. Total consideration amounted to HKD 24.71 million.

Following the transaction, Fosun Pharma’s issued share count (excluding treasury shares) declined from 537.57 million to 536.11 million, while treasury shares increased from 14.37 million to 15.83 million. The company’s total issued share capital remains unchanged at 551.94 million shares.

Since the current share-repurchase mandate was approved on 16 June 2026, Fosun Pharma has bought back 4.86 million shares, equivalent to 0.90% of the shares outstanding on the mandate date. All repurchased shares are held in treasury, and no cancellations have been executed to date.

Under Hong Kong Stock Exchange listing rules, Fosun Pharma is restricted from issuing new shares or disposing of treasury shares until 14 October 2026, 30 days after the latest repurchase.